TDB Backs Indigenous Stroke Treatment Device Manufacturing

Story BySaloni Tyagi

•

TDB Backs Indigenous Stroke Treatment Device Manufacturing

The project is expected to reduce reliance on expensive imports by providing high-quality, affordable alternatives produced in India.

The Technology Development Board (TDB), under the Department of Science and Technology (DST), has approved financial support for M/s S3V Vascular Technologies Limited, Mysuru.

The funding supports the company’s project titled “Integrated Manufacturing of Mechanical Thrombectomy Kit for Treatment of Acute Ischemic Stroke,” aimed at advancing stroke care through indigenous innovation.

The initiative marks a significant step ahead for India’s medtech innovation ecosystem.

It will involve setting up an advanced, upstream integrated manufacturing facility at the Medical Devices Park in Oragadam, Sriperumbudur, Chennai.

This facility will focus on the development and production of mechanical thrombectomy kits, critical tools used to treat acute ischemic stroke caused by large vessel occlusion.

Thrombectomy has been shown to offer significantly better outcomes than conventional thrombolysis, helping reduce long-term disability and paralysis, and making a clear difference between “PARALYSIS and RECOVERY.”

The project is expected to reduce reliance on expensive imports by providing high-quality, affordable alternatives produced in India. S3V also intends to integrate these stroke-care devices into national health schemes such as Ayushman Bharat, tapping into a domestic market estimated at USD 2 billion.

In addition, the company will work with hospitals across India to deliver simulator-based training programs, particularly targeting young interventionalists in Tier-II cities where stroke incidence remains high.

Regarding the development, Rajesh Kumar Pathak, Secretary, TDB, said, “TDB is proud to support S3V’s vision of building India’s first comprehensive neuro-intervention manufacturing ecosystem. This project reflects our continued commitment to making India a global hub for affordable, high-end medical technology, especially in areas of critical public health need like stroke care. The company’s focus on integrating these devices into Ayushman Bharat further aligns with the national goal of inclusive healthcare access.”

S3V Vascular Technologies is on track to become the first Indian company to design and manufacture the full range of neuro-intervention devices domestically.

These will include microcatheters, aspiration catheters, guidewires, and stent retriever systems, all produced within an integrated upstream facility.

The company also plans to file patents for several core innovations, including the clot retriever head design, braid-over-coil catheter structures, and new process technologies.

“With Technology Development Boards’ backing, we are setting a new benchmark in indigenous MedTech manufacturing. Our integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in Mechanical Thrombectomy but also reduces India’s dependency on import of the raw materials used in manufacturing of these critical complex lifesaving medical devices. We have initiated the CE and USFDA approval process for these devices to expand our access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe and USA. We’re committed to delivering world-class innovation, designed, engineered, and made entirely in India to the World,” Dr NG Vijaya Gopal, Managing Director of S3V Vascular Technologies, added.